N-(4-fluorobenzyl)-7-(2-methylpyridin-4-yl)quinazolin-4-amine | 1384181-61-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: N-(4-fluorobenzyl)-7-(2-methylpyridin-4-yl)quinazolin-4-amine
• 英文别名: N-[(4-fluorophenyl)methyl]-7-(2-methylpyridin-4-yl)quinazolin-4-amine
• CAS: 1384181-61-6
• 化学式: C₂₁H₁₇FN₄
• 分子量: 344.391
• InChiKey: RDTKQAZJRATOCU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  50.7
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Compound as WNT Signaling Inhibitor, Composition, and Use Thereof
  申请人：An Songzhou

  公开号：US20150119387A1

  公开（公告）日：2015-04-30

  The present invention relates to a compound having the structure of Formula I as inhibitor of WNT signal transduction pathways, as well as a composition comprising the compound. Further, the present invention relates to the use of the compound and the method of inhibiting the WNT signal transduction pathways.

  本发明涉及一种具有Formula I结构的化合物作为WNT信号传导途径的抑制剂，以及包含该化合物的组合物。此外，本发明涉及该化合物的使用以及抑制WNT信号传导途径的方法。
• [EN] COMPOUNDS FOR TREATMENT OF FIBROSIS DISEASES<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE MALADIES DE FIBROSE
  申请人：AN SONGZHU

  公开号：WO2014159733A1

  公开（公告）日：2014-10-02

  The present invention relates to compounds as inhibitor of WNT signal transduction pathway, as well as a composition comprising the same. Further, the present invention relates to the use of the compounds in the treatment of fibrosis. Fibrosis is the formation of excess fibrous connective tissue in an organ or tissue in a reparative or reactive process. Fibrosis is the end result of chronic inflammatory reactions induced by a variety of stimuli including persistent infections, autoimmune reactions, allergic responses, chemical insults, radiation, and tissue injury.

  本发明涉及作为WNT信号传导途径抑制剂的化合物，以及包含这些化合物的组合物。此外，本发明涉及利用这些化合物治疗纤维化。纤维化是在器官或组织中以修复或反应过程形成过多纤维结缔组织的现象。纤维化是由各种刺激引起的慢性炎症反应的最终结果，这些刺激包括持续感染、自身免疫反应、过敏反应、化学侵害、辐射和组织损伤。
• [EN] COMPOUNDS FOR TREATMENT OF CANCER<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DU CANCER
  申请人：CUREGENIX INC

  公开号：WO2014165232A1

  公开（公告）日：2014-10-09

  The present invention relates to compounds as inhibitor of WNT signal transduction pathway, as well as a composition comprising the same. Further, the present invention relates to the use of the compounds in the treatment of cancer.

  本发明涉及作为WNT信号传导途径抑制剂的化合物，以及包含这些化合物的组合物。此外，本发明涉及将这些化合物用于癌症治疗。
• [EN] COMPOUND AS WNT SIGNALING INHIBITOR, COMPOSITION, AND USE THEREOF<br/>[FR] COMPOSÉ COMME INHIBITEUR DE LA VOIE DE SIGNALISATION WNT, COMPOSITION ET UTILISATION ASSOCIÉE
  申请人：CUREGENIX INC

  公开号：WO2013185353A1

  公开（公告）日：2013-12-19

  The present invention relates to a compound having the structure of Formula I as inhibitor of WNT signal transduction pathways, as well as a composition comprising the compound. Further, the present invention relates to the use of the compound and the method of inhibiting the WNT signal transduction pathways.

  本发明涉及一种具有Formula I结构的化合物，作为WNT信号转导途径的抑制剂，以及包含该化合物的组合物。此外，本发明涉及该化合物的使用以及抑制WNT信号转导途径的方法。
• [EN] COMPOUND AS WNT SIGNALING INHIBITOR, COMPOSITION, AND USE THEREOF<br/>[FR] COMPOSÉ EN TANT QU'INHIBITEUR DE SIGNALISATION DE WNT, COMPOSITION ET APPLICATIONS
  申请人：CUREGENIX INC

  公开号：WO2012088712A1

  公开（公告）日：2012-07-05

  A compound as inhibitor of WNT signal transduction pathways, as well as a composition comprising the compound is disclosed. Further, the use of the compound and the method of inhibiting the WNT signal transduction pathways are also disclosed.

  一种作为WNT信号传导途径抑制剂的化合物，以及包含该化合物的组合物被揭示。此外，还公开了该化合物的使用以及抑制WNT信号传导途径的方法。